APAC Cell Therapy Market

APAC Cell Therapy Market Size (2023 to 2028)

The market size for cell therapy in the APAC region is estimated to be growing at a CAGR of 34.08% from 2023 to 2028.

One of the key drivers promoting the growth of the cell therapy market in the Asia Pacific includes advancements in the therapy landscape in terms of efficiency and production. The SARS-CoV-2 pandemic has fuelled the market even more, as there are currently no effective treatments for infection, especially in severe forms. In addition, genomic variants are to blame for various changes in patients' clinical symptoms. As a result, personalized treatment, which includes cell treatments, has been identified as a feasible treatment option for alleviating these symptoms.

Furthermore, according to some research and evidence, elevated levels of cytokines and chemokines that target lung tissue have been linked to several etiological factors. Because of their anti-inflammatory activity, ability to stimulate tissue regeneration, and immune-modulating capacity, exosomes generated from Mesenchymal Stem Cells (MSCs) are thought to offer potential therapeutic effectiveness in treating SARS-CoV-2 pneumonia.

Over the projected period, increased clinical research on exosomes to treat COVID-19 is also predicted to promote cell therapy market growth in the APAC region. In February 2020, for instance, Shanghai Public Health Clinical Centre teamed up with Wuhan Jinyintan Hospital and Cellular Biomedicine Group Ltd. to conduct clinical trials for inhalation of MSC-derived exosomes to treat coronavirus. In addition, the market's revenue generation is predicted to be boosted by increased approval and adoption of regenerative medicine in various Asian nations.

Despite technological breakthroughs and product development over the last decade, the market has been limited by a scarcity of skilled personnel who can operate advanced instruments such as flow cytometers and multi-mode readers. Flow cytometers and spectrophotometers, both technologically advanced and extremely difficult to use, generate a wide range of data outputs requiring expertise to analyze and examine. However, there is a demand-supply imbalance for competent people across the continent.

During the early months of the COVID-19 outbreak, the supply chain was affected, causing clinical studies to be delayed. To some extent, this may have a detrimental impact on the market. Biopharmaceutical companies, including industry heavyweights like Pfizer and Eli Lilly, have acknowledged clinical trial delays.

This research report on the APAC cell therapy market has been segmented and sub-segmented into the following categories.

By Technology:

• Somatic Cell Technology
• Cell Immortalization Technology
• Viral Vector Technology
• Genome Editing Technology
• Cell Plasticity Technology
• Three-Dimensional Technology

By Type:

• Autologous
• Allogeneic

By Cell Source:

• iPSCs
• Bone Marrow
• Umbilical Cord Blood-Derived Cells
• Adipose Tissues
• Neural Stem Cell

By Application:

• Musculoskeletal
• Cardiovascular
• Gastrointestinal
• Neurological
• Oncology
• Dermatology
• Wounds & Injuries
• Ocular
• Others

By End-User:

• Hospitals & Clinics
• Regenerative Medicine Centres
• Diagnostic & Research Centres
• Others

By Country:

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand, Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

During the forecast period, the APAC is forecasted to witness the fastest CAGR across the globe. The expansion of stem cell banking facilities and the resulting increase in stem cell production is expected to boost volumetric market capacity in the Asia Pacific on a regional and country level. The market is projected to rise as a result of this. Japan was the market leader in 2020, accounting for 17.1% of total sales. Its quick rise as a regenerative medicine research Centre is the reason for this. Because of the government's support, the country has become a hub for cellular therapy research. Government bodies have identified regenerative medicine, particularly cellular therapy, as critical components of the country's economic growth strategy.

Singapore is expected to increase quickly, followed by India and China, following the recent approval of Novartis' CAR-T treatment Kymriah in March 2022. Cell therapy development in the country has been hastened by rapid expansion in the field of stem cell research, as well as shifting regulations. Collaborations between hospitals, start-ups, and academic institutes are also expected to help accelerate the development and implementation of CAR T cell treatment in India.

Investment in the Indian sector is being driven by businesses like Immuneel Therapeutics, which is developing a specialized hub for cell therapy in the nation. The company's attempts to create cell therapy are part of the Make in India project, which aims to make this advanced medicine affordable to patients.

The project also aimed to give any global patient seeking this treatment in India access to it at a reduced cost than in other nations. This will make medical tourism more accessible in India, accelerating the market growth.

KEY MARKET PLAYERS:

Companies playing a vital role in the APAC cell therapy market profiled in this report are Merck KGaA and Thermo Fisher Scientific Inc, Lonza Group, Osiris Therapeutics, Inc., Danaher Corporation, Becton, Dickinson and Company, Sartorius AG, Fresenius Medical Care AG & Co. KGaA, FUJIFILM Irvine Scientific, Corning Incorporated, Mesoblast Ltd., Medipost Co., Ltd. Avantor, Inc., CellGenix GmbH, Bio-Techne Corporation, STEMCELL Technologies, SIRION Biotech GmbH, and Hemasoft.